Autres langues Madrigal Pharmaceuticals, Inc.

Actions

MDGL

US5588681057

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/04/2024			Varia. 5j.	Varia. 1 janv.
218,4 ^USD	+2,29 %		-4,36 %	-5,62 %

23/04	MADRIGAL PHARMACEUTICALS, INC. : BofA Securities dégrade le titre	ZM
23/04	MADRIGAL PHARMACEUTICALS, INC. : BofA Securities abaisse son opinion	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024	23/04
6 Stocks Positioned to Soar as Investors Focus on MASH	22/04
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	16/04
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing	11/04
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing	11/04
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	10/04
Madrigal Pharmaceuticals Says Rezdiffra Available in US	09/04
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	09/04
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	09/04
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing	04/04
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing	04/04
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing	04/04
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	03/04
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	19/03
EE.UU. - Valores a seguir en Wall Street (actualizado)	19/03
Madrigal Pharmaceuticals Prices $600 Million Public Offering	19/03
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering	19/03
Madrigal Pharmaceuticals Starts $500 Million Public Offering	18/03
Madrigal plans $500 million fund raising to prepare for NASH drug launch	18/03
Madrigal commences $500 million public offering of common stock	18/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Madrigal Pharmaceuticals, Inc.

Actions

MDGL

US5588681057

Autres langues

Filtres